A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration-Reference-Cited by-同舟云学术

A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration

Published:2018-02 Issue: Volume:68 Page:185-191
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Peterschmitt M. Judith,Cox Gerald F.,Ibrahim Jennifer,MacDougall James,Underhill Lisa H.,Patel Palni,Gaemers Sebastiaan J.M.

Funder

Sanofi Genzyme

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference27 articles.

1. Gaucher disease;Grabowski,2013

2. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment;Grabowski;Consens. Statement Eur. J. Pediatr.,2004

3. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease;Charrow;Arch. Intern. Med.,2000

4. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future;Goker-Alpan;Mol. Genet. Metab.,2011

5. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis;Mistry;Br. J. Haematol.,2009

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The natural history of Gaucher disease type 1 in 31 patients over a median of 15 years: a retrospective study;Internal Medicine Journal;2024-08-27

2. Enhancing access to treatment for Gaucher disease in India: The need for indigenous manufacturing;Journal of Biosciences;2024-02-20

3. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158;Journal of Clinical Medicine;2023-05-04

4. Re: Response letter to Sanofi’s communication related to “the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States”;Journal of Medical Economics;2023-04-17

5. Plasma glucosylsphingosine correlations with baseline disease burden and response to eliglustat in two clinical trials of previously untreated adults with Gaucher disease type 1;Molecular Genetics and Metabolism;2023-03